Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
European Journal of Cancer (Oxford, England : 1990)|November 16, 2004
Gene expression microarray technologies in the development of new therapeutic agentsPaul A Clarke, Robert te Poele, Paul Workman
Blood|September 30, 2004
Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathwayThomas Powles, Robert te Poele, Jonathan Shamash, et al.
Chemical Research in Toxicology|October 20, 2007
AHR- and DNA-damage-mediated gene expression responses induced by benzo(a)pyrene in human cell linesSarah L Hockley, Volker M Arlt, Daniel Brewer, et al.
Cell Cycle (Georgetown, Tex.)|January 30, 2009
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human gliomaSandrine Guillard, Paul A Clarke, Robert Te Poele, et al.
Breast Cancer Research and Treatment|August 4, 2007
Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell linesTracey D Bradshaw, Erica L Stone, Valentina Trapani, et al.
Molecular Cancer Therapeutics|November 16, 2004
Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: antisense down-regulation of exon 5 alters target gene expression and inhibits cell survivalJane Renshaw, Rosanne M Orr, Michael I Walton, et al.
Molecular Cancer Therapeutics|December 20, 2007
Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activityFlorence Chan, Chongbo Sun, Meg Perumal, et al.
Nature Communications|February 14, 2025
Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapyJoseph A Newman, Angeline E Gavard, Nergis Imprachim, et al.
NAR Cancer|March 16, 2026
Human DEAH-box helicase 8 regulates HSF1-mediated stress response and cancer-associated pre-mRNA splicing in tumour cellsJennifer R Tall, Robert Te Poele, Alexandra Vasile, et al.
Molecular Oncology|October 25, 2017
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitorSteven R Whittaker, Clare Barlow, Mathew P Martin, et al.
Pageof 2